Table 3 Regular use of analgesics in the absence or presence of contraindications
Unadjusted | Age- and sex-adjusted | |||||
|---|---|---|---|---|---|---|
Contraindicationa | Absent | Present | Absent | Present | p value | Potential clinical consequence |
% (n) | % (n) | % | % | |||
Non-steroidal anti-inflammatory drugs | ||||||
Chronic kidney disease (6834/10.1) | 11.2 (686) | 8.6 (59) | 11.6 | 12.0 | .802 | Acute renal failure, disease progression |
GI ulcers | ||||||
Ulcers (11,516/7.4) | 12.8 (1365) | 12.0 (102) | 11.8 | 12.6 | .509 | GI ulceration and complications |
Ulcers or use of GI-protective drugs (11,516/10.7) | 12.7 (1301) | 13.4 (166) | 11.6 | 14.1 | .014 | GI ulceration and complications |
CVD | ||||||
High primary CVD risk (9000/13.0) | 14.4 (1125) | 11.1 (129) | 12.1 | 13.5 | .220 | Increased risk of CVD |
Stroke, MI, angina pectoris (12,540/9.6) | 13.3 (1506) | 6.7 (80) | 12.1 | 8.8 | .003 | Increased risk of CVD |
Hypertension (12,725/49.1) | 14.2 (922) | 11.3 (705) | 11.5 | 12.5 | .122 | Increased blood pressure |
Paracetamol | ||||||
CVD | ||||||
High primary CVD risk (9000/13.0) | 14.5 (1139) | 9.7 (113) | 11.6 | 12.6 | .401 | Possible increased risk of CVD |
Stroke, MI, angina pectoris (12,540/9.6) | 13.8 (1565) | 9.9 (119) | 12.3 | 12.8 | .712 | Possible increased risk of CVD |